2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

VAL cells

" in MedChemExpress (MCE) Product Catalog:

52

Inhibitors & Agonists

3

Fluorescent Dyes

2

Biochemical Assay Reagents

13

Peptides

2

Inhibitory Antibodies

2

Click Chemistry

2

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16658
    Z-VAD(OMe)-FMK
    Maximum Cited Publications
    200 Publications Verification

    Z-VAL-Ala-Asp(OMe)-FMK

    		 Caspase Cancer
    Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) is a cell-permeable and irreversible pan-caspase inhibitor . Z-VAD(OMe)-FMK is an ubiquitin carboxy-terminal hydrolase L1 (UCHL1) inhibitor. Z-VAD(OMe)-FMK irreversibly modifies UCHL1 by targeting the active site of UCHL1 .
    Z-VAD(OMe)-FMK
  • HY-13233A
    Talabostat mesylate
    40+ Cited Publications

    VAL-boroPro mesylate; PT100 mesylate

    		 Dipeptidyl Peptidase Inflammation/Immunology Cancer
    Talabostat mesylate (Val-boroPro mesylate; PT100 mesylate) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC50 < 4 nM; Ki = 0.18 nM) and the inhibitor of fibroblast activation protein (FAP) (IC50 = 560 nM), inhibits DPP8/9 (IC50 = 4/11 nM; Ki = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC50 = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities .
    Talabostat mesylate
  • HY-131296
    5-A-RU-PABC-Val-Cit-Fmoc
    5+ Cited Publications

    		 Drug Derivative Inflammation/Immunology
    5-A-RU-PABC-Val-Cit-Fmoc is the proagent of 5-A-RU . 5-A-RU, a precursor of bacterial Riboflavin, is a mucosal-associated invariant T (MAIT) cells activator. 5-A-RU forms potent MAIT-activating antigens via non-enzymatic reactions with small molecules, such as glyoxal and methylglyoxal, which are derived from other metabolic pathways .
    5-A-RU-PABC-Val-Cit-Fmoc
  • HY-13233
    Talabostat

    VAL-boroPro; PT100

    		 Dipeptidyl Peptidase Inflammation/Immunology Cancer
    Talabostat (Val-boroPro; PT100) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC50 < 4 nM; Ki = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein (FAP) (IC50 = 560 nM), inhibits DPP8/9 (IC50 = 4/11 nM; Ki = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC50 = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities .
    Talabostat
  • HY-112099
    Mc-Val-Cit-PAB-Cl

    		ADC Linker Cancer
    Mc-Val-Cit-PAB-Cl is a cleavable ADC linker. Mc-Val-Cit-PAB-Cl can be used to conjugate MMAE and antibody to form antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE with IC50s of 3.3 and 0.95 nM for BJAB and WSU cell lines in cytotoxicity assay).
    Mc-Val-Cit-PAB-Cl
  • HY-P99612
    Farletuzumab ecteribulin

    MORAb-202

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
    Farletuzumab ecteribulin
  • HY-164729
    FZ-AD005

    		Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis Cancer
    FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The Kd value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .
    FZ-AD005
  • HY-P4322
    H-Ile-Lys-Val-Ala-Val-OH
    1 Publications Verification

    		 ERK Akt Neurological Disease Cancer
    H-Ile-Lys-Val-Ala-Val-OH is one of the most potent active sites of laminin-1. H-Ile-Lys-Val-Ala-Val-OH promotes cell adhesion, neurite outgrowth, and tumor growth. H-Ile-Lys-Val-Ala-Val-OH stimulates BMMSC population growth and proliferation by activating MAPK/ERK1/2 and PI3K/Akt signalling pathways .
    H-Ile-Lys-Val-Ala-Val-OH
  • HY-157763
    Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1

    		PROTAC-Linker Conjugates for PAC Btk Cancer
    Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 is a cleavable linker-payload conjugate and cereblon-binding BTK bifunctional degrader. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 induces BTK degradation and exerts cytotoxic effects when delivered via CD79b monoclonal antibody. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1, when formulated as a CD79b antibody-drug conjugate, achieves sustained in vivo BTK degradation in tumor-bearing mice with reduced systemic payload exposure. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 can be used for the research of activated b-cell-like diffuse large b-cell lymphoma (ADC linker: (HY-130944); PROTAC: (HY-163295)) .
    Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1
  • HY-125956
    Aurkin A

    		Aurora Kinase Apoptosis Cancer
    Aurkin A is an allosteric inhibitor for the interaction between Aurora A Kinase (also known also Aurka) and TPX2, through targeting the TPX2 binding sites with Kd of 3.77 μM. Aurkin A can disrupt polyploidy induced by Alisertib (HY-10971) and increase apoptosis of tumor cells. Aurkin A can be used in research on mitosis and cancer .
    Aurkin A
  • HY-141860
    PSMA-Val-Cit-PAB-MMAE

    		PSMA Microtubule/Tubulin Reactive Oxygen Species (ROS) Cytochrome P450 Cancer
    PSMA-Val-Cit-PAB-MMAE is a small-molecule conjugate targeting PSMA, with Monomethyl auristatin E (MMAE) (HY-15162) as its cytotoxic payload. PSMA-Val-Cit-PAB-MMAE binds to PSMA, thereby being delivered into PSMA-expressing prostate cancer cells. Subsequently, the Val-Cit linker is cleaved under the mediation of cathepsin B, releasing active MMAE. PSMA-Val-Cit-PAB-MMAE inhibits CYP3A4 activity (IC50 = 11.2 μM), induces intracellular ROS production and oxidative stress, disrupts the cytoskeleton through microtubule destabilization, and induces prostate cancer cell death. PSMA-Val-Cit-PAB-MMAE can be used in research related to prostate cancer .
    PSMA-Val-Cit-PAB-MMAE
  • HY-172287
    DBCO-PEG2-Val-Cit-PAB-MMAE

    		ADC Linker Cancer
    DBCO-PEG2-Val-Cit-PAB-MMAE is an ADC linker featuring a DBCO group, a Val-Cit dipeptide, a PAB motif, and an MMAE warhead. The DBCO group is a click chemistry handle which readily reacts with azide groups, while the Val-Cit is a protease-cleavable dipeptide which releases the MMAE warhead into cells via an elimination mechanism.
    DBCO-PEG2-Val-Cit-PAB-MMAE
  • HY-P1407
    Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone TFA

    		MALT1 NF-κB MMP Cancer
    Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone TFA is an irreversible MALT1 protein inhibitor. Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone TFA inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression .
    Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone TFA
  • HY-126584
    H-Val-Val-OH

    VAL-VAL

    		 Drug Intermediate Oligopeptide Cotransporter Others
    H-Val-Val-OH (Val-Val) is a stereochemistry-dependent substrate and inhibitor of apical oligopeptide transporters. H-Val-Val-OH undergoes apical intracellular accumulation in human intestinal cells via carrier-mediated transport, and inhibits the uptake of Cephalexin (HY-B0200) through interaction with transporters. Substitution of L-valine with D-valine in H-Val-Val-OH abolishes its binding ability to apical oligopeptide transporters .
    H-Val-Val-OH
  • HY-177578
    NN3201

    		Antibody-Drug Conjugates (ADCs) c-Kit Apoptosis Microtubule/Tubulin ERK Akt Caspase Cancer
    NN3201 is a c-Kit-targeting antibody-drug conjugate (ADC) with high affinity (KD = 0.19 pM). NN3201 is composed of 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (HY-178219) and an anti-c-Kit human monoclonal antibody NN2101 (HY-P991293). NN3201 rapidly internalizes and inhibits stem cell factor (SCF)-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits no Fc-mediated effector functions antibody-dependent cell-mediated cytotoxicity (ADCC)/complement-dependent cytotoxicity (CDC) due to reduced FcγR binding. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models. NN3201 can be used in small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) and acute myeloid leukemia (AML) research [1][2].
    NN3201
  • HY-P3726
    Lys-Gln-Ala-Gly-Asp-Val

    		Integrin Inflammation/Immunology Cancer
    Lys-Gln-Ala-Gly-Asp-Val (KQAGDV) is the six most carboxyl-terminal amino acids in the fibrinogen γ-chain sequence. Lys-Gln-Ala-Gly-Asp-Val is a cell adhesion peptide which is mediated through the α2bβ3 integrin. Lys-Gln-Ala-Gly-Asp-Val is a potent adhesion ligand for smooth muscle cells (SMCs) .
    Lys-Gln-Ala-Gly-Asp-Val
  • HY-P4668
    Valylleucine

    VAL-Leu; H-VAL-Leu-OH

    		 Bacterial Infection
    Valylleucine (Val-Leu; H-Val-Leu-OH) is a branched-chain dipeptide that can enter cells independently via bacterial dipeptide transport systems, and is hydrolyzed by dipeptidases to release Val and Leu. Valylleucine, as a model peptide, has its α-amino pK determined to be 7.90 by combining FDNB reaction kinetics with potentiometric titration .
    Valylleucine
  • HY-P4668A
    Valylleucine TFA

    VAL-Leu TFA; H-VAL-Leu-OH TFA

    		 Bacterial Infection
    Valylleucine (Val-Leu; H-Val-Leu-OH) TFA is a branched-chain dipeptide that can enter cells independently via bacterial dipeptide transport systems, and is hydrolyzed by dipeptidases to release Val and Leu. Valylleucine TFA, as a model peptide, has its α-amino pK determined to be 7.90 by combining FDNB reaction kinetics with potentiometric titration .
    Valylleucine TFA
  • HY-P4532
    Ac-Leu-Val-Lys-Aldehyde

    		Cathepsin Neurological Disease
    Ac-Leu-Val-Lys-Aldehyde is a potent cathepsin B inhibitor with IC50s of 4 nM. Ac-Leu-Val-Lys-Aldehyde significantly reduces quinolinic acid (HY-100807)-induced striatal cell death and causes accumulation of LC3-II .
    Ac-Leu-Val-Lys-Aldehyde
  • HY-178219
    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Apoptosis Cancer
    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE contains a linker and bioactive small molecule toxins MMAE (HY-15162). Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE can conjugate with NN2101 (HY-P991293) (anti c-Kit) for synthesizing NN3201. NN3201 rapidly internalizes and inhibits SCF-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models, such as small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) .
    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE
  • HY-12362G
    Val-cit-PAB-OH

    		ADC Linker Cancer
    Val-cit-PAB-OH GMP is a GMP grade Val-cit-PAB-OH (HY-12362). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Val-cit-PAB-OH is a degradable ADC linker.
    Val-cit-PAB-OH
  • HY-20336G
    Mc-Val-Cit-PABC-PNP

    		ADC Linker Cancer
    Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .
    Mc-Val-Cit-PABC-PNP
  • HY-161780
    Maleimide-PEG8-Val-Ala-PAB-SNS032

    		Drug-Linker Conjugates for ADC CDK Cancer
    Maleimide-Val-Ala-PAB-SNS032 is a conjugate of ADC toxin and linker. SNS032 is an inhibitor for CDK, inhibiting the cell cycle at G1/S phase and cell viability of cancer cells. Maleimide-Val-Ala-PAB is a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 can be utilized for the synthesis of ADC molecules .
    Maleimide-PEG8-Val-Ala-PAB-SNS032
  • HY-P5989
    Calpain inhibitor V

    Mu-VAL-HPh-FMK

    		 Antibiotic Infection
    Calpain inhibitor V (Mu-Val-HPh-FMK) is a cell-permeable and irreversible inhibitor of calpain that has anti-chlamydial activity .
    Calpain inhibitor V
  • HY-108137A
    Z-L(D-Val)G-CHN2

    		Cathepsin HSV SARS-CoV Infection
    Z-L(D-Val)G-CHN2 is the isoform of Z-LVG-CHN2 (HY-108137). Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of cysteine proteinase. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 displays an inhibition on HSV whereas no significant effect on poliovirus replication. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC50=190 nM) via inhibition of SARS-COV-2 3CL pro protease .
    Z-L(D-Val)G-CHN2
  • HY-P3972
    H-ILE-ARG-VAL-VAL-MET-OH

    		TGF-β Receptor Cancer
    H-ILE-ARG-VAL-VAL-MET-OH is a pentapeptide from C7 with a domain that supports cell attachment. H-ILE-ARG-VAL-VAL-MET-OH is also the sequence fragment that binds to the thrombospondin-1 (TS1) receptor .
    H-ILE-ARG-VAL-VAL-MET-OH
  • HY-152919
    Mal-amide-PEG8-Val-Cit-PAB-OH

    		ADC Linker Cancer
    Mal-amide-PEG8-Val-Cit-PAB-OH is a cleavable ADC linker featuring a maleimide, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB functional group. Maleimide is used to covalently bind free thiols on the cysteine residues of proteins. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery with the help of the PAB structure.
    Mal-amide-PEG8-Val-Cit-PAB-OH
  • HY-W800837
    t-Boc-N-amido-PEG4-Val-Cit

    		ADC Linker Cancer
    t-Boc-N-amido-PEG4-Val-Cit is a protease-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit dipeptide. The Val-Cit dipeptide is cleavable by cell proteases and features a carboxylic acid which is free for coupling reactions with amines to form amides. The Boc can be removed under acidic conditions to reveal a free primary amine, which may be used in a variety of reactions such as coupling or reductive amination.
    t-Boc-N-amido-PEG4-Val-Cit
  • HY-P4544
    Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone

    		MALT1 NF-κB MMP Cancer
    Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone is an irreversible MALT1 protein inhibitor. Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression .
    Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone
  • HY-W800625
    Boc-PEG4-Val-Cit-PAB-OH

    		ADC Linker Cancer
    Boc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Boc protecting group may be removed with acid to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
    Boc-PEG4-Val-Cit-PAB-OH
  • HY-W800621
    Fmoc-PEG2-Val-Cit-PAB-OH

    		ADC Linker Cancer
    Fmoc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine for use in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
    Fmoc-PEG2-Val-Cit-PAB-OH
  • HY-W800623
    Fmoc-PEG6-Val-Cit-PAB-OH

    		ADC Linker Cancer
    Fmoc-PEG6-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
    Fmoc-PEG6-Val-Cit-PAB-OH
  • HY-W800622
    Fmoc-PEG4-Val-Cit-PAB-OH

    		ADC Linker Cancer
    Fmoc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
    Fmoc-PEG4-Val-Cit-PAB-OH
  • HY-W800624
    Boc-PEG2-Val-Cit-PAB-OH

    		ADC Linker Cancer
    Boc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Boc protecting group may be removed with acid to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
    Boc-PEG2-Val-Cit-PAB-OH
  • HY-W800814
    Azido-PEG8-Amido-Val-Cit-PAB

    		ADC Linker Cancer
    Azido-PEG8-Amido-Val-Cit-PAB is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. As this enzyme is only present in the lysosome, the ADC payload will be released only in the cell. Azido will react with DBCO, BCN or other alkyne groups through click chemistry. PEG spacer increases aqueous solubility. Reagent grade, for research purpose.
    Azido-PEG8-Amido-Val-Cit-PAB
  • HY-W011254
    Ac-VAD-CHO

    Ac-VAL-Ala-Asp-CHO

    		 Caspase Cancer
    Ac-VAD-CHO (Ac-Val-Ala-Asp-CHO) is a pan-caspase inhibitor. Ac-VAD-CHO inhibits dissipation of MMP and cytochrome c release in hypoxia-exposed cells .
    Ac-VAD-CHO
  • HY-W800618
    NH2-PEG3-Val-Cit-PAB-OH

    		ADC Linker Others
    NH2-PEG3-Val-Cit-PAB-OH is a cleavable ADC linker featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.
    NH2-PEG3-Val-Cit-PAB-OH
  • HY-W800617
    NH2-PEG1-Val-Cit-PAB-OH

    		ADC Linker Cancer
    NH2-PEG1-Val-Cit-PAB-OH is a cleavable ADC linker intermediate featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.
    NH2-PEG1-Val-Cit-PAB-OH
  • HY-W800619
    NH2-PEG4-Val-Cit-PAB-OH

    		ADC Linker Others
    NH2-PEG4-Val-Cit-PAB-OH is a cleavable ADC linker featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.
    NH2-PEG4-Val-Cit-PAB-OH
  • HY-W800620
    NH2-PEG6-Val-Cit-PAB-OH

    		ADC Linker Others
    NH2-PEG6-Val-Cit-PAB-OH is a cleavable ADC linker featuring a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The primary amine is free to perform a wide variety of reactions such as coupling with carboxylic acids, reductive aminations with ketones or aldehydes, or other more specialized uses such as in SNAr reactions or heterocyclic chemistry. The Val-Cit dipeptide is cleaved by cellular proteases within the cell to allow for efficient payload delivery via an elimination mechanism within the PAB structure.
    NH2-PEG6-Val-Cit-PAB-OH
  • HY-P99803
    Clervonafusp alfa

    VAL-1221

    		 Glycosidase Others
    Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
    Clervonafusp alfa
  • HY-P4900
    Fluorescein-6-carbonyl-Asp(OMe)-Glu(OMe)-Val-DL-Asp(OMe)-fluoromethylketone

    		Caspase Others
    Fluorescein-6-carbonyl-Asp(OMe)-Glu(OMe)-Val-DL-Asp(OMe)-fluoromethylketone is a cell-permeable, non-toxic inhibitor that binds irreversibly to activated caspase-3 in apoptotic cells. The fluorescence intensity can be measured by flow cytometry, microwell plate reader, or fluorescence microscopy .
    Fluorescein-6-carbonyl-Asp(OMe)-Glu(OMe)-Val-DL-Asp(OMe)-fluoromethylketone
  • HY-186131
    Val-CDCA

    		Drug Derivative HBV Infection
    Val-CDCA is a chenodeoxycholate (CDCA) and C-24 L-Valine (HY-N0717) conjugate. Val-CDCA inhibits taurocholate uptake in human NTCP-stably transfected HEK293 cells. Val-CDCA can be used for HBV infection .
    Val-CDCA
  • HY-185494
    Mal-Val-Lys-PAB-CBI-PBD dimer

    		Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker Cancer
    Mal-Val-Lys-PAB-CBI-PBD dimer is a Drug-Linker Conjugates for ADC. Mal-Val-Lys-PAB-CBI-PBD dimer consists of the ADC Cytotoxin CBI-PBD dimer and a linker Mal-Val-Lys-PAB. Mal-Val-Lys-PAB-CBI-PBD dimer exhibits alkylating activity at A-T-rich DNA minor groove adenine residues, disrupting DNA integrity. Mal-Val-Lys-PAB-CBI-PBD dimer induces cancer cell growth inhibition and cellular death. Mal-Val-Lys-PAB-CBI-PBD dimer can be used for the research of cancer .
    Mal-Val-Lys-PAB-CBI-PBD dimer
  • HY-160756
    Val-Cit-Exatecan

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Val-Cit-Exatecan is a peptide-linked anti-tumor payload that can be used for the synthesis of antibody-drug conjugates (ADC). Val-Cit-Exatecan consists of DNA TopI inhibitor Exatecan (HY-13631) and a cathepsin-cleavable ADC linker (valine-citrulline). Val-Cit-Exatecan can be used in the research of colorectal cancer, gastric cancer, breast cancer, non-small cell lung cancer, ovarian cancer, head and neck cancer, pancreatic cancer, cervical cancer, and melanoma .
    Val-Cit-Exatecan
  • HY-142079
    Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE

    		Drug Derivative Cancer
    Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE (compound 62) is a drug-linker conjugate that contains a monomethyl auristatin E (MMAE) drug moiety, which is linked to a bromoacetamide-containing extension unit via a valine-citrulline (Val-Cit) dipeptide and a self-immolative p-aminobenzyl (PAB) spacer. Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE is applicable to the research of breast cancer, anaplastic large cell lymphoma and lung adenocarcinoma .
    Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE
  • HY-185428
    TRS-005

    		Antibody-Drug Conjugates (ADCs) CD20 Cancer
    TRS-005 is an anti-CD20 ADC, formed by conjugating an anti-CD20 monoclonal antibody to MMAE (HY-15162) via a Val-Cit (HY-140014) linker. TRS-005 targets CD20-positive tumor cells and delivers MMAE into cells through receptor-mediated endocytosis. TRS-005 can be used for research on relapsed/refractory B-cell non-Hodgkin lymphoma (specifically diffuse large B-cell lymphoma) .
    TRS-005
  • HY-171982
    ATII

    		Biochemical Assay Reagents Others
    ATII (Traseolide), a Polycyclic musk fragrance, is a hydrophobic hapten. ATII has no genotoxicity in the human lymphocytes and the human hepatoma cell line Hep G2. ATII can be bound by antibody M02/05/01 (H93 Val) with superior binding capacity. ATII can be conjugated to carrier proteins for antigen design .
    ATII
  • HY-P992171
    ADCT-701 Antibody

    HuBa-1-3D

    		 ADC Antibody EGFR Neurological Disease Cancer
    ADCT-701 Antibody is a humanized IgG1 antibody against hDLK-1 and an ADC antibody. ADCT-701 Antibody can be conjugated with the PBD dimer cytotoxin SG3199 (HY-101161) via the cleavable Val-Ala (HY-W007035) linker to construct the ADC ADCT-701. ADCT-701 Antibody can be used in the research of neuroblastoma, hepatocellular carcinoma, small cell lung cancer, and rhabdomyosarcoma .
    ADCT-701 Antibody
  • HY-183282
    LC-U7-44

    		Deubiquitinase Cancer
    LC-U7-44 is a potent USP7 inhibitor with an IC50 of 0.96 μM. LC-U7-44 binds to the hydrophobic catalytic pocket of USP7, forming hydrogen bonds with Gln297, Arg408, Asp295, Val296, and Gln351, and hydrophobic interactions with Leu406. LC-U7-44 exerts anti-proliferative effects on prostate cancer cells. LC-U7-44 can be used for the research of prostate cancer .
    LC-U7-44

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: